

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/593,180	
			Filing Date	September 13, 2006	
			First Named Inventor	Slade et al.	
			Art Unit	1626	
Examiner Name	Unknown				
Sheet	1	of	7	Attorney Docket Number	5062.03

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		5,192,753	03-09-1993	McGeer et al.	
		5,434,170	07-18-1995	Andrulis	
		5,455,169	10-03-1995	Mullan	
		5,603,959	02-18-1997	Horrobin et al.	
		5,643,960	07-01-1997	Breitner et al.	
		5,695,774	12-09-1997	Clark	
		5,985,930	11-16-1999	Pasinetti	
		6,025,395	02-15-2000	Breitner et al.	
		6,160,018	12-12-2000	Wechter et al.	
		6,160,618	12-12-2000	Garner	
		6,184,248	02-06-2001	Lee et al.	
		6,255,347	07-03-2001	Xiaotao et al.	
		6,469,055	10-22-2002	Lee et al.	
		6,821,997	11-23-2004	Rodriguez	
		6,911,466	06-28-2005	Koo et al.	
		2005-0186559	08-25-2005	Koo et al.	
		2006-0004086	01-05-2006	Koo et al.	
		7,097,998	08-29-2006	Koo et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)			
	1F	AU	01/257022	05-19-2005	Galasko et al.	
	2F	WO	01/78721	10-25-2001	Koo et al.	
	3F	WO	05/092062	03-21-2005	Slade et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/593,180	
			Filing Date	September 13, 2006	
			First Named Inventor	Slade et al.	
			Art Unit	1626	
			Examiner Name	Unknown	
Sheet	2	of	7	Attorney Docket Number	5062.03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1A	AKOHO et al., "A Study on Binding Modes of Nonsteroidal Anti-inflammatory Drugs to COX1 and COX2 as Obtained by Dock4.0," <i>J. Chem. Software</i> , 1999, 5(3):1-13.	
	2A	AMIN et al., "The pleiotropic functions of aspirin: mechanisms of action," <i>Cell. Mol. Life Sci.</i> , 1999, 56:305-312.	
	3A	ANDREASEN et al., "Cerebrospinal Fluid β -Amyloid ₍₁₋₄₂₎ in Alzheimer Disease," <i>Arch. Neurol.</i> , 1999, 56:673-680.	
	4A	BAYLY et al., "Structure-Based Design of Cox-2 Selectivity Into Flurbiprofen," <i>Bioor. Med. Chem. Lett.</i> , 1999, 9:307-312.	
	5A	BICKFORD et al., "Long-Term Treatment of Male F344 Rats with Deprenyl: Assessment of Effects on Longevity, Behavior, and Brain Function," <i>Neurobiology of Aging</i> , 1997, 18(3):309-318.	
	6A	BLACKER et al., "The Genetics of Alzheimer Disease," <i>Arch. Neurol.</i> , 1998, 55:294-296.	
	7A	BRAAK et al., "Neuropathological staging of Alzheimer-related changes," <i>Acta. Neuropathol.</i> , 1991, 82:239-259.	
	8A	BREITNER et al., "Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs," <i>Neurobiol. Aging</i> , 1995, 16(4):523-30.	
	9A	BREITNER et al., "Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study," <i>Neurology</i> , February 1994, 44:227-232.	
	10A	CAMMISULI et al., "Effects of extended electrical kindling on exploratory behavior and spatial learning," <i>Behav. Brain Res.</i> , 1997, 89:179-190.	
	11A	CANAPARO et al., "Determination of Ibuprofen in human plasma by high-performance liquid chromatography: validation and application in pharmacokinetic study," <i>Biomed. Chromatogr.</i> , 2000, 14:219-226.	
	12A	CHEN et al., "A learning deficit related to age and β -amyloid plaques in a mouse model of Alzheimer's disease," <i>Nature</i> , 2000, 408:975-979.	
	13A	CITRON et al., "Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β -amyloid precursor protein by different protease activities," <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:13170-13175.	
	14A	COMBS et al., "Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β -Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPAR γ Agonists," <i>J. Neurosci.</i> , 2000, 20(2):558-567.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/593,180	
			Filing Date	September 13, 2006	
			First Named Inventor	Slade et al.	
			Art Unit	1626	
Examiner Name	Unknown				
Sheet	3	of	7	Attorney Docket Number	5062.03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	15A	CORTON et al., "Central Role of Peroxisome Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators," <i>Annu. Rev. Pharmacol.</i> , 2000, 40:491-518.	
	16A	COTRAN et al., <i>Pathologic Basis of Disease</i> , Sixth Edition, 1999, W.B. Saunders Company, Philadelphia, p. 1332, Table 30-2.	
	17A	CRONSTEIN et al., "Targets for Antiinflammatory Drugs," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 1995, 35:449-462.	
	18A	CRYER et al., "Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs," <i>Am. J. Med.</i> , 1998, 104:413-421	
	19A	DEWITT, "Cox-2-Selective Inhibitors: The New Super Aspirins," <i>Mol. Pharmacol.</i> , 1999, 55(4):625-631.	
	20A	DUBOIS et al., "Cyclooxygenase in biology and disease," <i>FASEB J.</i> , 1998, 12:1063-1073.	
	21A	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <i>J. Clin. Invest.</i> , 2003, 112(3):440-449.	
	22A	FOLSTEIN et al., "Mini-Mental State" – A Practical Method for Grading the Cognitive State of Patients for the Clinician," <i>J. Psychiat. Res.</i> , 1975, 12:189-198.	
	23A	FRAUTSCHY et al., "Animal Model – Microglial Response to Amyloid Plaques in APPsw Transgenic Mice," <i>Am. J. Pathol.</i> , 1998, 152:307-317.	
	24A	GALASKO et al., "An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease," <i>Alzheimer Disease and Associated Disorders</i> , 1997, 11(Suppl. 2):S33-S39.	
	25A	GALASKO et al., "High Cerebrospinal Fluid Tau and Low Amyloid β 42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype," <i>Arch. Neurol.</i> , 1998, 55:937-945.	
	26A	HALLIDAY et al., "Alzheimer's Disease and Inflammation: A Review of Cellular and Therapeutic Mechanisms," <i>Clin. Exp. Pharmacol. Physiol.</i> , 2000, 27:1-8.	
	27A	HAUGABOOK et al., "Reduction of A β accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin," <i>FASEB J.</i> , 2000, 16-18.	
	28A	HE et al. "PPAR δ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs," <i>Cell</i> , 1999, 99:335-345.	
	29A	HIGAKI et al., "Inhibition of β -Amyloid Formation Identifies Proteolytic Precursors and Subcellular Site of Catabolism," <i>Neuron</i> , 1995, 14:651-659.	
	30A	HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 1996, 274:99-102.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/593,180	
			Filing Date	September 13, 2006	
			First Named Inventor	Slade et al.	
			Art Unit	1626	
			Examiner Name	Unknown	
Sheet	4	of	7	Attorney Docket Number	5062.03

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	31A	KALGUTKAR et al., "Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> , 2000, 97(2):925-930.		
	32A	KALGUTKAR et al., "Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors," <i>J. Med. Chem.</i> , 2000, 43:2860-2870.		
	33A	KATO et al., "Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes," <i>Journal of Pharmacy and Pharmacology</i> , 2001, 53:1679-1685.		
	34A	KAWARABAYASHI et al., "Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease," <i>J. Neurosci.</i> , 2001, 21(2):372-381.		
	35A	KHACHATURINAN, "Diagnosis of Alzheimer's Disease," <i>Arch. Neurol.</i> , 1985, 42:1097-1105.		
	36A	KITAMURA et al., "Increased Expression of Cyclooxygenases and Peroxisome Proliferator-Activated Receptor- γ in Alzheimer's Disease Brains," <i>Biochem. Biophys. Res. Comm.</i> , 1999, 254:582-586.		
	37A	KLAFKI et al., "The Carboxyl Termini of β -Amyloid Peptides 1-40 and 1-42 Are Generated by Distinct γ -Secretase Activities," <i>J. Biol. Chem.</i> , 1996, 271(45):28655-28659.		
	38A	KOO et al., "Evidence That Production and Release of Amyloid β -Protein Involves the Endocytic Pathway," <i>J. Biol. Chem.</i> , 1994, 269(26):17386-17389.		
	39A	KOO et al., "Trafficking of cell-surface amyloid β -protein precursor," <i>J. Cell Sci.</i> , 1996, 109:991-998.		
	40A	KOPAN et al., "Signal transduction by activated mNotch: Importance of proteolytic processing and its regulation by the extracellular domain," <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:1683-1688.		
	41A	KOUP et al., "A Single and Multiple Dose Pharmacokinetic and Metabolism Study of Meclofenamate Sodium," <i>Biopharm. Drug Dispos.</i> , 1990, 11:1-15.		
	42A	LEE et al., "Regulation of APP Synthesis and Secretion by Neuroimmunophilin Ligands and Cyclooxygenase Inhibitors," <i>Annals New York Academy of Sciences</i> , 2000, 920:261-268.		
	43A	LEWIS et al., "Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein," <i>Nature Genetics</i> , 2000, 25:402-405.		
	44A	LIM et al., "Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease," <i>J. Neurosci.</i> , 2000, 20(15):5709-5714.		
	45A	LU et al., "A second cytotoxic proteolytic peptide derived from amyloid β -protein precursor," <i>Nature Medicine</i> , 2000, 6(4):397-404.		
	46A	MCGEER et al., "Anti-inflammatory drugs and Alzheimer disease," <i>Lancet</i> , 1990, 335(8696):1037.		
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/593,180	
			Filing Date	September 13, 2006	
			First Named Inventor	Slade et al.	
			Art Unit	1626	
Sheet	5	of	7	Examiner Name	Unknown
				Attorney Docket Number	5062.03

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	47A	MCGEER et al., "Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies," <i>Neurology</i> , 1996, 47(2):425-32.		
	48A	MCKHANN et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," <i>Neurology</i> , 1984, 34(7):939-944.		
	49A	MCLENDON et al., "Cell-free assays for γ -secretase activity," <i>FASEB J.</i> , 2000, 14(15):2383-2386		
	50A	MIRRA et al., "Making the Diagnosis of Alzheimer's Disease – A Primer for Practicing Pathologists," <i>Arch. Pathol. Lab. Med.</i> , 1993, 117:132-144.		
	51A	MIRRA et al., "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)," <i>Neurology</i> , 1991, 41:479-486.		
	52A	MOHS, "Comprehensive and Neuropsychologic Evaluations – The Alzheimer's Disease Assessment Scale," <i>International Psychogeriatrics</i> , 1996, 8(2):195-203.		
	53A	MONTINE et al., "Increased CSF F ₂ -isoprostane concentration in probable AD," <i>Neurology</i> , 1999, 52:562-565.		
	54A	MURPHY et al., "A Simple and Rapid Test of Sensorimotor Function in the Aged Rat," <i>Neurobiology of Learning and Memory</i> , 1995, 64:181-186.		
	55A	MURPHY et al., "Presenilin 1 Regulates Pharmacologically Distinct γ -Secretase Activities," <i>J. Biol. Chem.</i> , 2000, 275(34):26277-26284.		
	56A	NETLAND et al., "Indomethacin Reverses the Microglial Response to Amyloid β -Protein", <i>Neurobiology of Aging</i> , February 1998, 19(3):201-4.		
	57A	PERETTO et al., "Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β -Amyloid ₁₋₄₂ Secretion", <i>Journal of Medicinal Chemistry</i> , March 21, 2005, pages A-P.		
	58A	PEREZ et al., "Mutagenesis Identifies New Signals for β -Amyloid Precursor Protein Endocytosis, Turnover, and the Generation of Secreted Fragments, Including A β 42," <i>J. Biol. Chem.</i> , 1999, 274(27):18851-18856.		
	59A	PEROLA et al., "Successful Virtual Screening of a Chemical Database for Farnesyltransferase Inhibitor Leads," <i>J. Med. Chem.</i> , 2000, 43:401-408.		
	60A	PIAZZA et al., "Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis," <i>Cancer Res.</i> , 1995, 55:3110-3116.		
	61A	RICK et al., "Short Intertrial Intervals Impair Water Maze Performance in Old Fischer 344 Rats," <i>J. Gerontol. Biol. Sci.</i> , 1996, 51A(4):B253-B260.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/593,180	
			Filing Date	September 13, 2006	
			First Named Inventor	Slade et al.	
			Art Unit	1626	
			Examiner Name	Unknown	
Sheet	6	of	7	Attorney Docket Number	5062.03

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	62A	RIENDEAU et al., "Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays," <i>Can. J. Physiol. Pharmacol.</i> , 1997, 75:1088-1095.	
	63A	ROGERS et al., "Clinical trial of indomethacin in Alzheimer's disease", <i>Neurology</i> , August 1993, 43:1609-1611.	
	64A	SAGI et al., "The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κ B Kinase, and NF κ B, Do Not Reduce Amyloid β 42 Production," <i>J. Biol. Chem.</i> , 2003, 278(34):31825-31830.	
	65A	SISODIA et al., "Identification and Transport of Full-Length Amyloid Precursor Proteins in Rat Peripheral Nervous System," <i>J. Neurosci.</i> , 1993, 13(7):3136-3142.	
	66A	SMITH et al., "Cyclooxygenases: Structural, Cellular, and Molecular Biology," <i>Annu. Rev. Biochem.</i> , 2000, 69:145-182.	
	67A	SUNDERLAND et al., "Longitudinal Stability of CSF Tau Levels in Alzheimer Patients," <i>Biol. Psychiatry</i> , 1999, 46:750-755.	
	68A	SUZUKI et al., "An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (β APP ₇₁₇) Mutants," <i>Science</i> , 1994, 264:1336-1340.	
	69A	WANG et al., "The Profile of Soluble Amyloid β Protein in Cultured Cell Media," <i>J. Biol. Chem.</i> , 1996, 271(50):31894-31902.	
	70A	WEGGEN et al., "A subset of NSAIDs lower amyloidogenic A β 42 independently of cyclooxygenase activity," <i>Nature</i> , 2001, 414:212-216.	
	71A	WEGGEN et al., "A β 42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain," <i>J. Biol. Chem.</i> , 2003, 278(33):30748-30754.	
	72A	WEGGEN et al., "Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β 42 Production by Direct Modulation of γ -Secretase Activity," <i>J. Biol. Chem.</i> , 2003, 278(34):31831-31837.	
	73A	WILTFANG et al., "Improved electrophoretic separation and immunoblotting of beta-amyloid (A β) peptides 1-40, 1-42, and 1-43," <i>Electrophoresis</i> , 1997, 18:527-532.	
	74A	WOLFE et al., "A Substrate-Based Difluoro Ketone Selective Inhibits Alzheimer's γ -Secretase Activity," <i>J. Med. Chem.</i> , 1998, 41:6-9.	
	75A	WOLFE et al., "Are Presenilins Intramembrane-Cleaving Proteases? Implications for the Molecular Mechanism of Alzheimer's Disease," <i>Biochemistry</i> , 1999, 38(35):11223-11230.	
	76A	YUAN et al., "Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons," <i>J. Neurosci. Methods</i> , 1999, 88:45-54.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden,

1Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 C.F.R. 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to

the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**